AtriCure, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael H. Carrel
- Full Time Employees
- 1,350
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 7555 Innovation Way Mason OH United States 45040
- IPO Date
- Aug 5, 2005
- CIK
- 0001323885
- Website
- atricure.com
- Similar Companies
- Business
- AtriCure, Inc. develops, manufactures, and sells advanced medical devices primarily for the surgical treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Its core product portfolio includes surgical ablation systems such as the Isolator® Synergy™ Access® Clamp, Isolator® Synergy™ Clamps, and the Isolator® Transpolar Pen; the AtriClip® devices for LAA exclusion including models like AtriClip PRO®, AtriClip FLEX™, and their Mini variants; cryoSPHERE® devices and related probes for cryo nerve block therapy targeting pain management; and minimally invasive surgical instruments including the EPi-Ease™ Epicardial Access Device and atrial lift systems. The company also offers hybrid total thoracoscopic therapy for long-standing persistent Afib. Founded in 2000 and headquartered in Mason, Ohio, AtriCure operates globally, targeting cardiac surgeons, electrophysiologists, and hospitals involved in cardiac surgery. Recent major changes include the successful launch of new products like the AtriClip Flex Mini and cryoSPHERE MAX probes, which have driven accelerated growth in appendage and pain management segments. The company achieved significant revenue growth for 2025, projecting revenues between $532 million and $534 million, which represents double-digit percentage increases year over year. AtriCure also advanced development in pulse field ablation (PFA) technology for cardiac surgery and expanded its global manufacturing and R&D facilities in Mason, Ohio. Additionally, the company completed strategic acquisitions earlier, such as that of Estech, enhancing its surgical ablation portfolio with radio-frequency technologies. These developments reinforce AtriCure’s leadership position in surgical Afib treatments, LAA management, and postoperative pain therapies across multiple international markets.
Company News
AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results
AtriCure, Inc. (ATRC) Q3 2026 Earnings Call Transcript
What AtriCure (ATRC) Said on Its Q3 Earnings Call
Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics
AtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates
AtriCure Reports Third Quarter 2026 Financial Results
Riverwater Small Cap Strategy Q3 2026 Portfolio Update
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
AtriCure to Announce Third Quarter 2026 Financial Results
AtriCure (NASDAQ:ATRC) Reaches New 12-Month High – Here’s What Happened
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
AtriCure CTO Sells 3,657 Shares
Do Options Traders Know Something About AtriCure Stock We Don't?
AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
AtriCure: Promising Cardiovascular Surgical Platform
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors